Proteostasis Therapeutics Inc. (NASDAQ: PTI) is -51.32% lower on its value in year-to-date trading and has touched a low of $0.87 and a high of $2.72 in the current 52-week trading range. The PTI stock was last observed hovering at around $1.15 in the last trading session, with the day’s loss setting it -0.04% off its average median price target of $2.00 for the next 12 months. It is also 44.5% off the consensus price target high of $2.00 offered by 1 analysts, but current levels are 44.5% higher than the price target low of $2.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $1.11, the stock is 0.45% and 0.90% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.11 million and changing -3.48% at the moment leaves the stock -14.53% off its SMA200. PTI registered -25.50% loss for a year compared to 6-month loss of -25.50%. The firm has a 50-day simple moving average (SMA 50) of $1.0943 and a 200-day simple moving average (SMA200) of $1.2570.
The stock witnessed a 6.73% gain in the last 1 month and extending the period to 3 months gives it a 3.74%, and is -5.93% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.63% over the week and 8.05% over the month.
Proteostasis Therapeutics Inc. (PTI) has around 5 employees, a market worth around $58.94M and $0.00M in sales. Distance from 52-week low is 27.59% and -59.19% from its 52-week high. The company has generated returns on investments over the last 12 months (-98.00%).
Proteostasis Therapeutics Inc. (PTI) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Proteostasis Therapeutics Inc. (PTI) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Proteostasis Therapeutics Inc. is expected to release its quarterly report on 03/17/2021 and quarterly earnings per share for the current quarter are estimated at -$0.19.The EPS is expected to grow by 28.00% this year.
Proteostasis Therapeutics Inc. (PTI) Top Institutional Holders
55 institutions hold shares in Proteostasis Therapeutics Inc. (PTI), with 7.98M shares held by insiders accounting for 15.30% while institutional investors hold 26.65% of the company’s shares. The shares outstanding are 52.18M, and float is at 43.76M with Short Float at 2.50%. Institutions hold 22.57% of the Float.
The top institutional shareholder in the company is Ikarian Capital, LLC with over 4.78 million shares valued at $5.26 million. The investor’s holdings represent 9.16% of the PTI Shares outstanding. As of Sep 29, 2020, the second largest holder is Vanguard Group, Inc. (The) with 3.56 million shares valued at $3.92 million to account for 6.83% of the shares outstanding. The other top investors are Jennison Associates LLC which holds 2.29 million shares representing 4.39% and valued at over $2.52 million, while Blackrock Inc. holds 4.16% of the shares totaling 2.17 million with a market value of $2.39 million.
Proteostasis Therapeutics Inc. (PTI): Who are the competitors?
The company’s main competitors (and peers) include NeoGenomics Inc. (NEO) that is trading 89.24% up over the past 12 months. Natera Inc. (NTRA) is 225.69% up on the 1-year trading charts. Short interest in the company’s stock has fallen -28.44% from the last report on Oct 29, 2020 to stand at a total of 1.4 million short shares sold with a short interest ratio of 2.57.